Immunotherapy for multiple sclerosis: The curious case of interferon beta

Archives of Neurology

Volumn 66, Issue 10, 2009, Pages 1193-1194

  Stüve, Olaf ^a   Ransohoff, Richard M ^b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CCL1 CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON BETA SERINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; RECOMBINANT BETA INTERFERON; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT INTERFERON;

ANTIGEN PRESENTATION; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL ADHESION; CENTRAL NERVOUS SYSTEM; EDITORIAL; ENDOTHELIUM CELL; GLIA; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOTHERAPY; LEUKOCYTE MIGRATION; LEUKOCYTE ROLLING; LYMPHOID ORGAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT RESPONSE; DRUG EFFECT; METHODOLOGY; NOTE; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTERFERON TYPE I, RECOMBINANT; MULTIPLE SCLEROSIS;

EID: 70350443015     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.200     Document Type: Editorial

References (11)

1. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610-621.
2. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-661. (Pubitemid 23121951)
3. Paty DW, Li DK; UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):662-667.
4. Neighbour PA, Bloom BR. Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis. Proc Natl Acad Sci U S A. 1979;76(1):476-480. (Pubitemid 9110221)
5. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol. 1996;40(6):846-852. (Pubitemid 27044602)
6. Stüve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol. 1996;40(6):853-863. (Pubitemid 27044603)
7. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6(12):1182-1190. (Pubitemid 43045626)
8. Rebenko-Moll NM, Liu L, Cardona A, Ransohoff RM. Chemokines, mononuclear cells and the nervous system: heaven (or hell) is in the details. Curr Opin Immunol. 2006;18(6):683-689. (Pubitemid 44635175)
9. Cepok S, Schreiber H, Hoffmann S, et al. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol. 2009;66(10):1216-1223.
10. Mahad D, Callahan MK, Williams KA, et al. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain. 2006; 129(pt 1):212-223. (Pubitemid 43063772)
11. Shiow LR, Rosen DB, Brdickova N, et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature. 2006;440(7083):540-544.